药学学报, 2014, 49(11): 1528-1535
引用本文:
何笑荣, 刘志鹤, 季双敏, 刘滔滔, 李良, 周田彦, 卢炜. 中国患者人群中万古霉素的群体药代动力学研究及药效预测[J]. 药学学报, 2014, 49(11): 1528-1535.
HE Xiao-rong, LIU Zhi-he, JI Shuang-min, LIU Tao-tao, LI Liang, ZHOU Tian-yan, LU Wei. Population pharmacokinetics of vancomycin and prediction of pharmacodynamics in the Chinese people[J]. Acta Pharmaceutica Sinica, 2014, 49(11): 1528-1535.

中国患者人群中万古霉素的群体药代动力学研究及药效预测
何笑荣1,2, 刘志鹤2, 季双敏1, 刘滔滔3, 李良1, 周田彦1, 卢炜1
1. 北京大学药学院, 北京 100191;
2. 北京医院药学部, 药物临床风险与个体化应用评价北京市重点实验室, 北京 100730;
3. 广西医科大学第一附属医院, 广西 南宁 530021
摘要:
应用非线性混合效应模型(NONMEM)研究建立中国老年患者万古霉素的群体药代动力学模型。数据为回顾性收集的稀疏数据, 采用两中心共260例患者, 其中男177例、女83例共计619个血药浓度数据建立模型。采用一室型模型进行数据拟合。两中心数据以引入一个协变量SID(研究中心标识码)的方式考察对模型的影响。最终模型为:CL=(θbase+θmax×(1-e(-θ1×CLCR)))×θAge(Age/72),V=θv×θAge(Age/72), 其中的协变量为CLCr和Age, 模型CL和V的群体典型值分别2.91 L·h-1, 54.76 L。最终模型用Bootstrap法和NPDE法进行模型的内部验证, 另外采用34例患者的68个血药浓度数据进行模型的外部验证。Bootstrap法1 000次重复抽样和拟合, 通过所得参数的中位数和95% 的置信区间判断模型的稳健性。NPDE法和外部数据验证评价模型预测能力。在万古霉素的药效学评价中, 用万古霉素群体药动学模型预测的患者清除率计算相应的AUC0-24 h值, 以AUC0-24 h与MIC比值大于等于400作为临床有效治疗的指标来判断患者使用万古霉素的合理性。结果显示: 部分患者依常规给药时低于理想临床治疗剂量。本研究通过万古霉素的群体药动学模型结合患者的MIC、Age、CLCr及AUC0-24 h/MIC之间的关系来预测万古霉素的合理给药剂量, 为患者万古霉素的个体化给药提供参考。
关键词:    万古霉素      群体药代动力学模型      中国患者      药效学     
Population pharmacokinetics of vancomycin and prediction of pharmacodynamics in the Chinese people
HE Xiao-rong1,2, LIU Zhi-he2, JI Shuang-min1, LIU Tao-tao3, LI Liang1, ZHOU Tian-yan1, LU Wei1
1. School of Pharmaceutical Sciences, Peking University, Beijing 100191, China;
2. Department of Pharmacy, Beijing Hospital, Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation, Beijing 100730, China;
3. The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China
Abstract:
Population pharmacokinetics of vancomycin(VAN)in the Chinese patients was described by using nonlinear mixed-effects modeling(NONMEM). 619 VAN serum concentrations data from 260 patients including 177 males and 83 females were collected separately from two centers. A one-compartment model was used to describe this sparse data. No significant difference was observed between two center datasets by introducing SID covariate. The final model was as CL=(θbase+θmax×(1-e(-θ1×CLCR)))×θAge(Age/72) and V=θv×θAge(Age/72). The creatinine clearance(CLCr)and Age were identified as the most significant covariate in the final model. Typical values of clearance(CL)and volume of distribution(V)in the final model were 2.91 L·h-1 and 54.76 L, respectively. Internal model validation by Bootstrap and NPDE were performed to evaluate the robustness and prediction of the final model. The median and 95% confidence intervals for the final model parameters were based on 1000 Bootstraps. External model evaluation was conducted using an independent dataset that consisted of 34 patients to predict model performance. Pharmacodynamic assessment for VAN by AUC0-24 h to MIC ratios of over 400 was considered to be the best to predict treatment outcomes for patients. AUC0-24 h was calculated by clearance based on the above population model. The results indicate that the conventional dosing regimen probably being suboptimal concentrations in aged patients. The approach via population pharmacokinetic of VAN combined with the relationship of MIC, Age, CLCr and AUC0-24 h/MIC can predict the rational dose for attaining efficacy.
Key words:    vancomycin    population pharmacokinetics    Chinese patient    pharmacodynamic   
收稿日期: 2014-04-30
通讯作者: 卢炜
Email: luwei_pk@bjmu.edu.cn
相关功能
PDF(637KB) Free
打印本文
0
作者相关文章
何笑荣  在本刊中的所有文章
刘志鹤  在本刊中的所有文章
季双敏  在本刊中的所有文章
刘滔滔  在本刊中的所有文章
李良  在本刊中的所有文章
周田彦  在本刊中的所有文章
卢炜  在本刊中的所有文章

参考文献:
[1] Brink AJ. Does resistance in severe infections caused by methicillin-resistant Staphylococcus aureus give you the ‘creeps'? [J]. Curr Opin Crit Care, 2012, 18:451-459.
[2] Yeh KY, Yeh CM, Lin TY, et al. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia [J]. J Microb Immun Infect, 2012, 45: 214-220.
[3] Liu YL, Xu YC. Heterogeneous vancomycin-intermediate Staphylococcus aureus: a challenge in clinical practice [J]. Chin J Infect Chemother(中国感染与化疗杂志), 2013, 13: 495-498.
[4] Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin [J]. Clin Infect Dis, 2006, 42(suppl 1): S35-39.
[5] Gusack BJ. Pharmacokinetics in older persons [J]. Am J Geriatr Pharmacother, 2004, 2: 274-302.
[6] Rybak MJ, Lomaestro B, Rotsschaferj C, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of health-System Pharmacists, the infectious Diseases Society of America, and the Society of infectious Diseases Pharmacists [J]. Am J Health Syst Pharm, 2009, 66: 82-98.
[7] Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin- intermediate Staphylococcus aureus [J]. Clin Infect Dis, 2004, 38: 448-451.
[8] Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses(at least four grams per day)are associated with an increased incidence of nephrotoxicity [J]. Antimicrob Agents Chemother, 2008, 52: 1330-1336.
[9] Pritcard L, Baker C, Leggett J, et al. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity [J]. Am J Med, 2010, 123: 1143-1149.
[10] Wong-Beringer A, Joo J, Tse E, et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy [J]. Int J Antimicrob Agents, 2011, 37: 95-101.
[11] Revilla N, Martin-Suarez A, Perez MP, et al. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic / pharmacodynamic simulation [J]. Br J Clin Pharmacol, 2010, 70: 201-212.
[12] Sanchez JL, Dominguez AR, Lane JR, et al. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches [J]. Int J Clin Pharmacol Ther, 2010, 48: 525-533.
[13] Lo YL, van Hasselt JC, Heng SC, et al. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination [J]. Antimicrob Agents Chemother, 2010, 54: 2626-2632.
[14] Purwonugroho TA, Chulavatnatol S, Preechagoon Y, et al. Population pharmacokinetics of vancomycin in Thai patients [J]. Scientific World J, 2012, 2012: 1-8.
[15] Lindbom L, Ribbing J, Jonsson N. Perl-speaks-NONMEM(PsN)- a perl module for NONMEM related programming [J]. Comput Methods Programs Biomed, 2004, 75: 85-94.
[16] Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals(CWRES): a model diagnostic for the FOCE method [J]. Pharm Res, 2007, 24: 2187-2197.
[17] Brendel K, Comets E, Laffont C, et al. Evaluation of different tests based on observations for external model evaluation of population analyses [J]. J Pharmacokinet Pharmacodyn, 2010, 37: 49-65.
[18] Karlsson MO, Savic RM. Diagnosing model diagnostics [J]. Clin Pharm Ther, 2007, 82: 17-20.
[19] Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance [J]. Am J Med, 2006, 119: S37-S44.
[20] Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia [J]. Antimicrob Agents Chemother, 2013, 57: 1654-1663.
[21] Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant staphylococcus aureus and its association with attributable mortality during hospitalization [J]. Antimicrob Agents Chemother, 2012, 56: 634-638.
[22] Deng CH, Liu TT, Wu K, et al. Predictive performances of reported population pharmacokinetic models of vancomycin in Chinese adult patients [J]. J Clin Pharm Ther, 2013, 2013: 1-10.
[23] Deng CH, Liu TT, Zhou TY, et al. Initial Dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis [J]. Int J Clin Pharmacol Ther, 2013, 5: 407-415.
[24] Turnheim K. Pharmacokinetic dosage guidelines for elderly subjects [J]. Expert Opin Drug Metab Toxicol, 2005, 1: 33-48.
[25] Hu JY, Shi YG, Zhang J, et al. Pharmacokinetics of vanco­mycin in elderly and young healthy volunteers [J]. Chin J Infect Chemother(中国抗感染化疗杂志), 2003, 3: 138-142.
[26] Yamamoto M, Kuzuya T, Baba H, et al. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infective disease type [J]. J Clin Pharm Ther, 2009, 34: 473-483.
[27] Yasuhara M, Iga T, Zenda H, et al. Population pharmacoki­netics of vancomycin in Japanese adult patients [J]. Ther Drug Monit, 1998, 20: 139-148.
[28] Jung YH, Song KH, Cho JE, et al. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia [J]. Int J Antimicrob Agents, 2014, 43: 179-189.